|
1.
|
|
11 p, 865.1 KB |
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
/
Abrisqueta, Pau (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Medina, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Lu, Junyan (European Molecular Biology Laboratory (Alemanya)) ;
Alcoceba, Miguel (Centro de Investigación Biomédica en Red de Cáncer) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Boix, Joan (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Barbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bobillo, Sabela (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Marín-Niebla, Ana (Universitat Autònoma de Barcelona. Departament de Medicina) ;
González, Marcos (Centro de Investigación Biomédica en Red de Cáncer) ;
Zenz, Thorsten (University of Zurich. Department of Medical Oncology and Hematology) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona. Departament de Medicina)
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. [...]
2022 -  10.1182/bloodadvances.2022007508
Blood advances, Vol. 6 (august 2022) , p. 5763-5773
|
|
|
2.
|
|
10 p, 578.0 KB |
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma : a multicenter GELTAMO/FIL study
/
García-Sancho, Alejandro Martín (Hospital Universitario de Salamanca) ;
Bellei, Monica (Fondazione Italiana Linfomi (FIL) Onlus, Modena, Italy) ;
López-Parra, Miriam (Instituto de Investigación Biomédica de Salamanca) ;
Gritti, Giuseppe (, ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Cortés, María (Department of Statistics, Hospital Universitario de Salamanca / IBSAL, Salamanca, Spain) ;
Novelli, Silvana (Institut d'Investigació Biomèdica Sant Pau) ;
Panizo, Carlos (Clínica Universidad de Navarra) ;
Petrucci, Luigi (Sapienza University) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Dlouhy, Ivan (Hospital Clínic i Provincial de Barcelona) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Sancho, Juan M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramírez, María J. (Hematology Department, Hospital de Especialidades de Jerez de la Frontera, Cádiz, Spain) ;
Moraleda, José M. (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Carrillo, Estrella (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Jiménez-Ubieto, Ana I. (Hospital Universitario 12 de Octubre (Madrid)) ;
Jarque, Isidro (Instituto de Investigación Sanitaria La Fe) ;
Orsucci, Lorella (Candiolo Cancer Institute) ;
García-Torres, Estefanía (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Montalbán, Carlos (Department of Translational Research, MD Anderson Cancer Center, Madrid, Spain) ;
Dodero, Anna (Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ;
Arranz, Reyes (Hospital Universitario de la Princesa (Madrid)) ;
De las Heras, Natalia (Department of Hematology, Complejo Hospitalario de León, León, Spain) ;
Pascual, María J. (Hospital Regional Universitario de Málaga) ;
López-Jiménez, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Spina, Michelle (Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy) ;
Re, Alessandro (Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy) ;
de Villambrosia, Sonia González (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Federico, Massimo (University of Modena and Reggio Emilia) ;
Caballero, Dolores (Instituto de Investigación Biomédica de Salamanca) ;
Universitat Autònoma de Barcelona
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies that mostly have poor prognoses with currently available treatments. Upfront consolidation with autologous stem cell transplantation (ASCT) is frequently carried out, but its efficacy has never been investigated in randomized trials. [...]
2022 - 10.3324/haematol.2021.279426
Haematologica, Vol. 107 (march 2022) , p. 2675-2684
|
|
|
3.
|
|
6 p, 785.8 KB |
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
/
Bobillo, Sabela (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Joffe, Erel (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Sermer, David (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Mondello, Patrizia (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Ghione, Paola (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Caron, Philip C. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Hamilton, Audrey (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Hamlin, Paul A. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Horwitz, Steven M. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Kumar, Anita (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Matasar, Matthew J. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Batlevi, Connie L. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Moskowitz, Alison (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Noy, Ariela (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Owens, Collette N. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Palomba, M. Lia (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Straus, David (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
von Keudell, Gottfried (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Dogan, Ahmet (Memorial Sloan Kettering Cancer Center. Department of Pathology) ;
Zelenetz, Andrew D. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Seshan, Venkatraman E. (Memorial Sloan Kettering Cancer Center) ;
Younes, Anas (Weill Cornell Medical College. Weill Cornell Department of Medicine)
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined the efficacy of different prophylactic regimens in 585 patients with newly diagnosed DLBCL and high-risk for CNS relapse, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like regimens from 2001 to 2017, of whom 295 (50%) received prophylaxis. [...]
2021 - 10.1038/s41408-021-00506-3
Blood Cancer Journal, Vol. 11 (june 2021)
|
|
|
4.
|
|
14 p, 3.9 MB |
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
/
Jiménez, Isabel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Tazón-Vega, Bárbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Abrisqueta, Pau (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Nieto Sáchica, Juan Camilo (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bobillo, Sabela (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Palacio-García, Carles (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Carabia, Júlia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Valdés-Mas, Rafael (DREAMgenics) ;
Munuera, Magdalena (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Puigdefàbregas, Lluís (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Parra, Genís (Universitat Pompeu Fabra) ;
Esteve-Codina, Anna (Universitat Pompeu Fabra) ;
Franco-Jarava, Clara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Terol, María José (Instituto de Investigación Sanitaria INCLIVA (València, Comunitat Valenciana)) ;
García-Marco, José Antonio (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Crespo, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia)
Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. [...]
2021 - 10.1186/s40364-021-00290-z
Biomarker Research, Vol. 9 (may 2021)
|
|
|
5.
|
|
9 p, 6.7 MB |
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
/
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ;
Mayor, Regina (Hospital Universitari Vall d'Hebron) ;
Raheja, Priyanka (Vall d'Hebron Institut d'Oncologia) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ;
Tazon-Vega, Barbara ;
Palacio-García, Carles (Vall d'Hebron Institut d'Oncologia) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Jimenez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Nieto Sáchica, Juan Camilo (Vall d'Hebron Institut d'Oncologia) ;
Montoro Gómez, Julia (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Ricarte, Francisco (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Simo, Marc (Hospital Universitari Vall d'Hebron) ;
Puigdefabregas, Lluis (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. [...]
2020 - 10.3324/haematol.2019.241208
Haematologica, Vol. 106 (february 2020) , p. 513-521
|
|
|
6.
|
|
13 p, 3.3 MB |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
/
Jiménez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Palacio-García, Carles (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Pagès, Carlota (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Nieto Sáchica, Juan Camilo (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Martinez-Ricarte, Fran (Hospital Universitari Vall d'Hebron) ;
Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ;
Perla, Cristóbal (Hospital Universitari Joan XXIII de Tarragona) ;
Céspedes Torrez, Dennis H. (Hospital Universitari Joan XXIII de Tarragona) ;
Boix, Joan (Vall d'Hebron Institut d'Oncologia) ;
Purroy i Zuriguel, Noèlia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Puigdefàbregas, Lluís (Vall d'Hebron Institut d'Oncologia) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia)
Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. [...]
2020 - 10.1007/s11060-020-03580-y
Journal of Neuro-Oncology, Vol. 149 (july 2020) , p. 13-25
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
